Shares of Cellceutix Corp. (CTIX.OB) have gained over 24% year-to-date, and the impending results from the company's phase II trial of Prurisol for psoriasis can have a significant impact on the stock price.
from RTT - Biotech http://ift.tt/1TOKorZ
via IFTTT
No comments:
Post a Comment